Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice

Marianna L. Ianzano, Stefania Croci, Giordano Nicoletti, Arianna Palladini, Lorena Landuzzi, Valentina Grosso, Dario Ranieri, Massimiliano Dall'Ora, Ilaria Santeramo, Milena Urbini, Carla De Giovanni, Pier Luigi Lollini, Patrizia Nanni

Research output: Contribution to journalArticle

Abstract

Human sarcomas arise suddenly, thus preempting the study of preneoplastic and early neoplastic lesions. To explore the natural history of these tumors we studied male mice carrying a heterozygous deletion of p53 and an activated HER-2/neu transgene (BALB-p53Neu mice), that develop urethral rhabdomyosarcomas with nearly full penetrance and early onset (4 months of age). Among genes prominently upregulated in preneoplastic tissue, and more highly expressed in tumors, we found the insulin-like growth factor 2 (Igf2) and tumor suppressors, p19Arf and p21Cip1. In urethral tissues of male mice p53 was less expressed than in female mice, whereas HER-2/neu was more expressed, a combination not found in other skeletal muscles of the same mice that could contribute to the anatomic and sexual specificity of BALB-p53Neu rhabdomyosarcoma. Upregulation of p19Arf and p21Cip1 was additively determined by HER-2/neu activation and by p53 inactivation. Silencing of p19Arf or p21Cip1 in rhabdomyosarcoma cell lines can inhibit cell growth and motility, thus suggesting that these genes can contribute to growth autonomy and malignancy of tumor cells. In vivo injection of gene-silenced cells highlighted selective variations in organ-specific metastatic ability, indicating that overexpression of p19Arf and p21Cip1 controlled both tumor cell-intrinsic properties and microenvironmental interactions. The onset of pelvic rhabdomyosarcoma in BALB-p53Neu male mice is triggered by the coincidental overexpression of HER-2/neu and hypoexpression of the residual p53 allele, that foster p53 loss, Igf2 autocriny and overexpression of p19Arf and p21Cip1, a phenotype that could provide novel potential targets for cancer prevention and therapy.

Original languageEnglish
Pages (from-to)108-119
Number of pages12
JournalOncotarget
Volume5
Issue number1
Publication statusPublished - 2014

Fingerprint

Rhabdomyosarcoma
Tumor Suppressor Genes
Transgenic Mice
Neoplasms
Somatomedins
Genes
Penetrance
Growth
Transgenes
Sarcoma
Cell Movement
Skeletal Muscle
Up-Regulation
Alleles
Phenotype
Cell Line
Injections

Keywords

  • HER-2
  • p19Arf
  • p21Cip1
  • p53
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. / Ianzano, Marianna L.; Croci, Stefania; Nicoletti, Giordano; Palladini, Arianna; Landuzzi, Lorena; Grosso, Valentina; Ranieri, Dario; Dall'Ora, Massimiliano; Santeramo, Ilaria; Urbini, Milena; De Giovanni, Carla; Lollini, Pier Luigi; Nanni, Patrizia.

In: Oncotarget, Vol. 5, No. 1, 2014, p. 108-119.

Research output: Contribution to journalArticle

Ianzano, ML, Croci, S, Nicoletti, G, Palladini, A, Landuzzi, L, Grosso, V, Ranieri, D, Dall'Ora, M, Santeramo, I, Urbini, M, De Giovanni, C, Lollini, PL & Nanni, P 2014, 'Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice', Oncotarget, vol. 5, no. 1, pp. 108-119.
Ianzano, Marianna L. ; Croci, Stefania ; Nicoletti, Giordano ; Palladini, Arianna ; Landuzzi, Lorena ; Grosso, Valentina ; Ranieri, Dario ; Dall'Ora, Massimiliano ; Santeramo, Ilaria ; Urbini, Milena ; De Giovanni, Carla ; Lollini, Pier Luigi ; Nanni, Patrizia. / Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. In: Oncotarget. 2014 ; Vol. 5, No. 1. pp. 108-119.
@article{affc3eae406647138254b3cdbf0ac31b,
title = "Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice",
abstract = "Human sarcomas arise suddenly, thus preempting the study of preneoplastic and early neoplastic lesions. To explore the natural history of these tumors we studied male mice carrying a heterozygous deletion of p53 and an activated HER-2/neu transgene (BALB-p53Neu mice), that develop urethral rhabdomyosarcomas with nearly full penetrance and early onset (4 months of age). Among genes prominently upregulated in preneoplastic tissue, and more highly expressed in tumors, we found the insulin-like growth factor 2 (Igf2) and tumor suppressors, p19Arf and p21Cip1. In urethral tissues of male mice p53 was less expressed than in female mice, whereas HER-2/neu was more expressed, a combination not found in other skeletal muscles of the same mice that could contribute to the anatomic and sexual specificity of BALB-p53Neu rhabdomyosarcoma. Upregulation of p19Arf and p21Cip1 was additively determined by HER-2/neu activation and by p53 inactivation. Silencing of p19Arf or p21Cip1 in rhabdomyosarcoma cell lines can inhibit cell growth and motility, thus suggesting that these genes can contribute to growth autonomy and malignancy of tumor cells. In vivo injection of gene-silenced cells highlighted selective variations in organ-specific metastatic ability, indicating that overexpression of p19Arf and p21Cip1 controlled both tumor cell-intrinsic properties and microenvironmental interactions. The onset of pelvic rhabdomyosarcoma in BALB-p53Neu male mice is triggered by the coincidental overexpression of HER-2/neu and hypoexpression of the residual p53 allele, that foster p53 loss, Igf2 autocriny and overexpression of p19Arf and p21Cip1, a phenotype that could provide novel potential targets for cancer prevention and therapy.",
keywords = "HER-2, p19Arf, p21Cip1, p53, Rhabdomyosarcoma",
author = "Ianzano, {Marianna L.} and Stefania Croci and Giordano Nicoletti and Arianna Palladini and Lorena Landuzzi and Valentina Grosso and Dario Ranieri and Massimiliano Dall'Ora and Ilaria Santeramo and Milena Urbini and {De Giovanni}, Carla and Lollini, {Pier Luigi} and Patrizia Nanni",
year = "2014",
language = "English",
volume = "5",
pages = "108--119",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "1",

}

TY - JOUR

T1 - Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice

AU - Ianzano, Marianna L.

AU - Croci, Stefania

AU - Nicoletti, Giordano

AU - Palladini, Arianna

AU - Landuzzi, Lorena

AU - Grosso, Valentina

AU - Ranieri, Dario

AU - Dall'Ora, Massimiliano

AU - Santeramo, Ilaria

AU - Urbini, Milena

AU - De Giovanni, Carla

AU - Lollini, Pier Luigi

AU - Nanni, Patrizia

PY - 2014

Y1 - 2014

N2 - Human sarcomas arise suddenly, thus preempting the study of preneoplastic and early neoplastic lesions. To explore the natural history of these tumors we studied male mice carrying a heterozygous deletion of p53 and an activated HER-2/neu transgene (BALB-p53Neu mice), that develop urethral rhabdomyosarcomas with nearly full penetrance and early onset (4 months of age). Among genes prominently upregulated in preneoplastic tissue, and more highly expressed in tumors, we found the insulin-like growth factor 2 (Igf2) and tumor suppressors, p19Arf and p21Cip1. In urethral tissues of male mice p53 was less expressed than in female mice, whereas HER-2/neu was more expressed, a combination not found in other skeletal muscles of the same mice that could contribute to the anatomic and sexual specificity of BALB-p53Neu rhabdomyosarcoma. Upregulation of p19Arf and p21Cip1 was additively determined by HER-2/neu activation and by p53 inactivation. Silencing of p19Arf or p21Cip1 in rhabdomyosarcoma cell lines can inhibit cell growth and motility, thus suggesting that these genes can contribute to growth autonomy and malignancy of tumor cells. In vivo injection of gene-silenced cells highlighted selective variations in organ-specific metastatic ability, indicating that overexpression of p19Arf and p21Cip1 controlled both tumor cell-intrinsic properties and microenvironmental interactions. The onset of pelvic rhabdomyosarcoma in BALB-p53Neu male mice is triggered by the coincidental overexpression of HER-2/neu and hypoexpression of the residual p53 allele, that foster p53 loss, Igf2 autocriny and overexpression of p19Arf and p21Cip1, a phenotype that could provide novel potential targets for cancer prevention and therapy.

AB - Human sarcomas arise suddenly, thus preempting the study of preneoplastic and early neoplastic lesions. To explore the natural history of these tumors we studied male mice carrying a heterozygous deletion of p53 and an activated HER-2/neu transgene (BALB-p53Neu mice), that develop urethral rhabdomyosarcomas with nearly full penetrance and early onset (4 months of age). Among genes prominently upregulated in preneoplastic tissue, and more highly expressed in tumors, we found the insulin-like growth factor 2 (Igf2) and tumor suppressors, p19Arf and p21Cip1. In urethral tissues of male mice p53 was less expressed than in female mice, whereas HER-2/neu was more expressed, a combination not found in other skeletal muscles of the same mice that could contribute to the anatomic and sexual specificity of BALB-p53Neu rhabdomyosarcoma. Upregulation of p19Arf and p21Cip1 was additively determined by HER-2/neu activation and by p53 inactivation. Silencing of p19Arf or p21Cip1 in rhabdomyosarcoma cell lines can inhibit cell growth and motility, thus suggesting that these genes can contribute to growth autonomy and malignancy of tumor cells. In vivo injection of gene-silenced cells highlighted selective variations in organ-specific metastatic ability, indicating that overexpression of p19Arf and p21Cip1 controlled both tumor cell-intrinsic properties and microenvironmental interactions. The onset of pelvic rhabdomyosarcoma in BALB-p53Neu male mice is triggered by the coincidental overexpression of HER-2/neu and hypoexpression of the residual p53 allele, that foster p53 loss, Igf2 autocriny and overexpression of p19Arf and p21Cip1, a phenotype that could provide novel potential targets for cancer prevention and therapy.

KW - HER-2

KW - p19Arf

KW - p21Cip1

KW - p53

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84893872565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893872565&partnerID=8YFLogxK

M3 - Article

C2 - 24334679

AN - SCOPUS:84893872565

VL - 5

SP - 108

EP - 119

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -